SEATTLE, WA -- (MARKET WIRE) -- February 27, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) has reviewed the U.S. Securities and Exchange Commission’s litigation release No. 20017 announcing the filing and settlement of securities fraud charges against hedge fund adviser, Crestview Capital Partners, LLC and one of its managing members, Stewart R. Flink. Among other things, the SEC charged Crestview and Mr. Fink with making fraudulent representations in connection with Targeted Genetics’ February 2004 registered direct offering.
